Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Cinnamomum zeylanicum
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Cinnamon, Type 2 diabetes, Diabetes, México, Cinnamomum zeylanicum, Randomized Controlled Trial, Glycated hemoglobin, Glucose control
Eligibility Criteria
Inclusion Criteria:
- Subjects with a prior medical diagnosis of T2D
- Mexican adults (> 18 years)
- Treatments only with oral hypoglycemic agents
- HbA1c >6.5% and <10%
- Attendees to two participating primary health care centers.
Exclusion Criteria:
- Patients who have an allergy to cinnamon or wheat flour.
- Treatments with insulin
- Gastrointestinal problems or any condition in cinnamon is not well tolerated or contraindicated
- Cardiovascular, hepatic or renal disease.
- Use of addictive substances as drugs.
- Pregnant or lactation
- Psychiatric condition that prevents adherence to treatment
- Use of a supplement with an effect on glucose
Sites / Locations
- C.A.A.P.S.
- ISSSTE Family Medicine Clinic
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Intervention group
Control group
Arm Description
Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
Outcomes
Primary Outcome Measures
Glycated hemoglobin
Change in glycated hemoglobin
Secondary Outcome Measures
Fasting plasma glucose
Change in fasting plasma glucose
Total cholesterol
Change in total cholesterol
HDL
Change in HDL Cholesterol
LDL
Change in LDL Cholesterol
Triglycerides
Change in Triglycerides
Weight
Change in Weight
Waist circumference
Change in waist circumference
Body Mass Index
Change in the Body Mass Index
Blood pressure
Change in blood pressure
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04023539
Brief Title
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
Official Title
Evaluation of the Effect of Cinnamomum Zeylanicum on Glycemic Levels of Mexican Adult Patients With Type 2 Diabetes at 3 Months: Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
September 4, 2019 (Actual)
Primary Completion Date
March 20, 2020 (Actual)
Study Completion Date
April 23, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Sonora
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Type 2 Diabetes (T2D) is protected against chronic hyperglycemia. This is one of the main causes of death in the country, being a public health problem worldwide. Some studies have shown that herbal products have beneficial effects in patients with diabetes by improving the metabolism of glucose and lipids. Cinnamomum Zeylanicum (C.Z.), colloquially cinnamon, is one of the components of the diet that has active biological substances with insulin mimetic properties. In Mexico, little has been investigated about the use of this therapy. Previous studies do not conclude if there is a statistically significant effect in the glycemic control of patients with diabetes. Therefore, it is proposed to evaluate the effect of the supplement consumption of C.Z. 3 months compared to a control group on the change in glycated hemoglobin (HbA1c) in Mexican adults with T2D. This is a randomized, single-blind clinical trial with T2D patients from the clinic CAAPS . Those that are divided into: intervention group with supplement of 2g daily C.Z. Oral route (capsules) for 90 days, and control group with placebo. The figures will be recorded: HbA1c, fasting plasma glucose, blood pressure, cholesterol, HDL, LDL, triglycerides, waist circumference, weight and body mass index.
Detailed Description
Cinnamon, in in vitro and in vivo studies, has been shown to have biologically active substances with mimetic properties of insulin. In 1990 an unidentified component of cinnamon was extracted and named as an insulin-enhancing factor. The components of cinnamon bark oil (Ceylon) contain cinnamaldehyde (75%), cinnamyl acetate (5%), caryophyllene (3.3%), linalool (2.4%) and eugenol (2.2%). It is believed that the modality in which cinnamon expresses its effect on blood glucose can be attributed to its active component cinnamaldehyde.
Within the 250 species of the Cinnamomum genus there are four types that are used as spice, the Cinnamomum Zeylanicum or Sri Lanka (also known as C. verum Ceylon) commonly referred to as "true cinnamon"; three very popular spices related to C. cassia are C. aromaticum (cinnamon china), C. loureirii (cinnamon vietnamese) and C. burmanni (cinnamon indonesia).
One important difference between "true cinnamon" and cinnamon cassia is its coumarin content. The content of coumarin in cinnamomum zeylanicum is too low to cause health risks, while the level of coumarin in Cinnamomum aromaticum appears to be much higher and may pose health risks if consumed in larger quantities and on a regular basis. The use of cinnamon cassia as a regular supplement with meals is not recommended or the daily dose has been restricted in many countries due to the toxic effects of Cinnamomum aromaticum on the liver and coagulation. In contrast, cinnamomum zeylanicum has been shown to contain a lower amount of coumarin, and therefore it may be possible to use it at higher doses without toxic effects for longer periods. In vivo studies with cinnamomum zeylanicum have not shown significant adverse effects or toxicity in liver, kidney and / or pancreas.
In a systematic review it was concluded that the evidence available in vitro and in vivo suggests that cinnamomum zeylanicum has antimicrobial, antiparasitic, anti-inflammatory and antioxidant properties. The authors also indicated that cinnamomum zeylanicum appears to lower blood glucose, serum cholesterol, and blood pressure, suggesting beneficial cardiovascular effects.
The mechanism of this hypoglycaemic action is not entirely clear, but can be attributed to an increase in serum insulin levels, storage of liver glycogen, better signaling of the insulin receptor, an insulinomimetic effect, or reduction of alpha activity intestinal -glucosidase. In clinical terms, these actions could lead to improvements in glycemic control and insulin sensitivity, and a possible reduction in the complications of diabetes.
In Mexico, little has been investigated on the use of this alternative therapy. In other countries, such as the United States, the United Kingdom, China, Pakistan and Germany, studies have been conducted on the potential effects of cinnamomum in in vitro, in vivo and in human studies. The effect of C. zeylanicum on glycemic control is inconclusive due to the contradictory results of the literature, some authors found statistically significant changes in glycosylated hemoglobin or fasting plasma glucose in randomized clinical trials compared with a placebo group. On the other hand, several authors report not having found significant changes in glucose levels in the study subjects.
In the case of the Mexican population, no scientific studies were found that address the use of cinnamomum as an alternative therapy-alone or combined-in the control of glycemic levels in patients with diabetes. Therefore, in this study we propose to evaluate the effect of cinnamomum zeylanicum supplement consumption at 3 months compared to a control group (placebo) on the change in HbA1c in Mexican adults with T2D.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Cinnamon, Type 2 diabetes, Diabetes, México, Cinnamomum zeylanicum, Randomized Controlled Trial, Glycated hemoglobin, Glucose control
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial This is a simple blind randomized clinical trial with patients with type 2 diabetes, the subjects will be divided into two groups, the intervention supplemented with 2 g daily of cinnamomum zeylanicum orally (capsules) and the control group with a placebo. There will be a follow-up of 3 months every two weeks to measure the variables of interest in the study.
Masking
Participant
Masking Description
A simple blinding (participants blinded to the belonging group). The person who will randomize the participants will not be involved in the recruitment of participants. This will be done when we have the total sample of participants.
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention group
Arm Type
Active Comparator
Arm Description
Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Cinnamomum zeylanicum
Intervention Description
Capsules of 2 g cinnamomum zeylanicum orally
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo capsules
Primary Outcome Measure Information:
Title
Glycated hemoglobin
Description
Change in glycated hemoglobin
Time Frame
baseline to 3 months
Secondary Outcome Measure Information:
Title
Fasting plasma glucose
Description
Change in fasting plasma glucose
Time Frame
baseline to 3 months
Title
Total cholesterol
Description
Change in total cholesterol
Time Frame
baseline to 3 months
Title
HDL
Description
Change in HDL Cholesterol
Time Frame
baseline to 3 months
Title
LDL
Description
Change in LDL Cholesterol
Time Frame
baseline to 3 months
Title
Triglycerides
Description
Change in Triglycerides
Time Frame
baseline to 3 months
Title
Weight
Description
Change in Weight
Time Frame
baseline to 3 months
Title
Waist circumference
Description
Change in waist circumference
Time Frame
baseline to 3 months
Title
Body Mass Index
Description
Change in the Body Mass Index
Time Frame
baseline to 3 months
Title
Blood pressure
Description
Change in blood pressure
Time Frame
baseline to 3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with a prior medical diagnosis of T2D
Mexican adults (> 18 years)
Treatments only with oral hypoglycemic agents
HbA1c >6.5% and <10%
Attendees to two participating primary health care centers.
Exclusion Criteria:
Patients who have an allergy to cinnamon or wheat flour.
Treatments with insulin
Gastrointestinal problems or any condition in cinnamon is not well tolerated or contraindicated
Cardiovascular, hepatic or renal disease.
Use of addictive substances as drugs.
Pregnant or lactation
Psychiatric condition that prevents adherence to treatment
Use of a supplement with an effect on glucose
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julio Alfredo García Puga, Ph.D.
Organizational Affiliation
Universidad de Sonora
Official's Role
Principal Investigator
Facility Information:
Facility Name
C.A.A.P.S.
City
Hermosillo
State/Province
Sonora
ZIP/Postal Code
83000
Country
Mexico
Facility Name
ISSSTE Family Medicine Clinic
City
Hermosillo
State/Province
Sonora
ZIP/Postal Code
83140
Country
Mexico
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22518078
Citation
Ranasinghe P, Perera S, Gunatilake M, Abeywardene E, Gunapala N, Premakumara S, Perera K, Lokuhetty D, Katulanda P. Effects of Cinnamomum zeylanicum (Ceylon cinnamon) on blood glucose and lipids in a diabetic and healthy rat model. Pharmacognosy Res. 2012 Apr;4(2):73-9. doi: 10.4103/0974-8490.94719.
Results Reference
background
Citation
Sangal A. Role of cinnamon as beneficial antidiabetic food adjunct: A review. Advaces in Applied Science Research. 2010;2(4):440-50
Results Reference
background
PubMed Identifier
24019277
Citation
Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med. 2013 Sep-Oct;11(5):452-9. doi: 10.1370/afm.1517.
Results Reference
background
PubMed Identifier
27618575
Citation
Costello RB, Dwyer JT, Saldanha L, Bailey RL, Merkel J, Wambogo E. Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review. J Acad Nutr Diet. 2016 Nov;116(11):1794-1802. doi: 10.1016/j.jand.2016.07.015. Epub 2016 Sep 8.
Results Reference
background
PubMed Identifier
19680836
Citation
Lungarini S, Aureli F, Coni E. Coumarin and cinnamaldehyde in cinnamon marketed in Italy: a natural chemical hazard? Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 Nov;25(11):1297-305. doi: 10.1080/02652030802105274.
Results Reference
background
PubMed Identifier
29282046
Citation
Ranasinghe P, Jayawardena R, Pigera S, Wathurapatha WS, Weeratunga HD, Premakumara GAS, Katulanda P, Constantine GR, Galappaththy P. Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. BMC Complement Altern Med. 2017 Dec 28;17(1):550. doi: 10.1186/s12906-017-2067-7.
Results Reference
background
PubMed Identifier
24148965
Citation
Ranasinghe P, Pigera S, Premakumara GA, Galappaththy P, Constantine GR, Katulanda P. Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): a systematic review. BMC Complement Altern Med. 2013 Oct 22;13:275. doi: 10.1186/1472-6882-13-275.
Results Reference
background
PubMed Identifier
22972104
Citation
Leach MJ, Kumar S. Cinnamon for diabetes mellitus. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007170. doi: 10.1002/14651858.CD007170.pub2.
Results Reference
background
PubMed Identifier
20854384
Citation
Akilen R, Tsiami A, Devendra D, Robinson N. Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. Diabet Med. 2010 Oct;27(10):1159-67. doi: 10.1111/j.1464-5491.2010.03079.x.
Results Reference
background
PubMed Identifier
14633804
Citation
Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003 Dec;26(12):3215-8. doi: 10.2337/diacare.26.12.3215.
Results Reference
background
Citation
Khan R, Khan Z, Hussain Shah S. Cinnamon May Reduce Glucose, Lipid and Cholesterol Level in Type 2 Diabetic Individuals. Pakistan J Nutr. 2010;9(5):430-3
Results Reference
background
PubMed Identifier
22749176
Citation
Lu T, Sheng H, Wu J, Cheng Y, Zhu J, Chen Y. Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes. Nutr Res. 2012 Jun;32(6):408-12. doi: 10.1016/j.nutres.2012.05.003. Epub 2012 Jun 14.
Results Reference
background
Citation
Sharma P, Sharma S, Agrawal RP, Agrawal V, Singhal S. A randomised double blind placebo control trial of cinnamon supplementation on glycemic control and lipid profile in type 2 diabetes mellitus. Aust J Herbal Med. 2012;24(1):52-7.
Results Reference
background
PubMed Identifier
16634838
Citation
Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, Stichtenoth DO, Hahn A. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest. 2006 May;36(5):340-4. doi: 10.1111/j.1365-2362.2006.01629.x.
Results Reference
background
PubMed Identifier
19734396
Citation
Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med. 2009 Sep-Oct;22(5):507-12. doi: 10.3122/jabfm.2009.05.080093.
Results Reference
background
PubMed Identifier
17563345
Citation
Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE. Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2236-7. doi: 10.2337/dc07-0098. Epub 2007 Jun 11. No abstract available.
Results Reference
background
PubMed Identifier
26362826
Citation
Mirfeizi M, Mehdizadeh Tourzani Z, Mirfeizi SZ, Asghari Jafarabadi M, Rezvani HR, Afzali M. Controlling type 2 diabetes mellitus with herbal medicines: A triple-blind randomized clinical trial of efficacy and safety. J Diabetes. 2016 Sep;8(5):647-56. doi: 10.1111/1753-0407.12342. Epub 2015 Dec 1.
Results Reference
background
PubMed Identifier
17718288
Citation
Suppapitiporn S, Kanpaksi N, Suppapitiporn S. The effect of cinnamon cassia powder in type 2 diabetes mellitus. J Med Assoc Thai. 2006 Sep;89 Suppl 3:S200-5.
Results Reference
background
PubMed Identifier
22973482
Citation
Vafa M, Mohammadi F, Shidfar F, Sormaghi MS, Heidari I, Golestan B, Amiri F. Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. Int J Prev Med. 2012 Aug;3(8):531-6.
Results Reference
background
PubMed Identifier
16549460
Citation
Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig WK, van Loon LJ. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr. 2006 Apr;136(4):977-80. doi: 10.1093/jn/136.4.977.
Results Reference
background
Learn more about this trial
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs